When is LSX Congress USA 2026?

LSX Congress USA 2026 ran Sep 23–24, 2026 at Hynes Convention Center in Boston, United States. The next edition, LSX USA Congress 2027, is Sep 21–23, 2027.

Where is LSX Congress USA 2026 held?

LSX Congress USA 2026 was held at Hynes Convention Center in Boston, United States.

Who sponsors LSX Congress USA 2026?

ConferenceGrid lists 16 sponsors, including Latham & Watkins, Axcelead Drug Discovery Partners,Inc., Brown Rudnick, Ernst & Young and Servier Monde.

This edition has endedNext: LSX USA CongressSep 21–23, 2027

Biotech

LSX Congress USA 2026

Name: LSX Congress USA 2026
Start: 2026-09-23
End: 2026-09-24
Location: Hynes Convention Center

This edition has ended

LSX Congress USA 2026 ran Sep 23–24, 2026 at Hynes Convention Center in Boston, United States. It is a Biotech conference that expected about 1,000 attendees. ConferenceGrid lists 174 speakers, 16 sponsors and 25 sessions. The next edition, LSX USA Congress 2027, is Sep 21–23, 2027.

Lineup updated Jun 16, 2026 · dates verified May 5, 2026

LSX Congress USA is where biotech companies from emerging startups to later-stage firms meet investors and pharma partners to power the next stage of growth. Attendees engage in 1:1 partnering, focused discussions on capital raising, investment strategies, commercialisation and pharma partnerships in the US life sciences sector. With tailored tracks, network…

Visit the official site

174Speakers

16Sponsors

25Sessions

179Companies · in total

Speakers

Programmed at LSX, in alphabetical order.

Aaron Schuchart

President and CEO · aether THERAPEUTICS

Adam Griffiths

Portfolio Manager, Partnering & Investment · Informa Connect

Aryeh Ganz

Managing Partner · Cornucopian Capital

Audrey Warner

Co-Founder & Managing Partner · 28 Capital

Bernard Cooney

Partner · Casdin Capital

Bibhash Mukhopadhyay

CEO · Sapient Biotech Investments, Sapient Biotech Investments; Miletus Biotechnology

Brian Goodman

Managing Director · Vida Ventures

Carla Bauer

Director, Oncology S&E, BD&L · Merck

Carlyle Rogers

Director, Licensing & Commercialization · East Carolina University

Chandler Monk

CEO · Cleaved Diagnostics

Chris Girardo

Assistant CMIO and Staff Pathologist · Ochsner Health

Christopher Tan

Executive Director, BD&L · MERCK & CO., INC

Claris Tsang Munksgaard

Director, Global Business Development · EMD Serono

Craig Kenesky

Partner · Brown Rudnick

Curt LaBelle

Managing Partner & Head, AXA IM Global Health Investment Fund · BNP Paribas Asset Management

Daniel Teo

Co-Founder & Managing Partner · Hunniwell Lake Ventures

Dan Zheng

Head of Regional Innovation and Partnerships, Center for External Innovation · Takeda Pharmaceutical Company Limited

David Crosslin

CEO · Sound Biology

David Lee

EVP & US CEO · Servier Pharmaceuticals

David Weingarten

Partner · Finnegan

Dawn Halkuff

CEO · Nari Therapeutic

Debra Yu

COO & Partner · Panacea Capital

Agenda

Selected from 25 sessions.

11:00am - 11:40am
Breaking into New Markets: Strategies for Global Biopharma Expansion
- Identifying high-growth regions and market opportunities - Navigating regulatory landscapes and compliance challenges - Building strategic partnerships to accelerate market entry
Market Opportunities & Commercialisation
11:00am - 11:40am
From Bench to Bedside: Accelerating the Translation of Breakthrough Biopharma Innovations
- Streamlining the journey from research to clinical application - Overcoming regulatory and operational hurdles in drug development - Enhancing patient access to life-saving thera…
Early Innovation & Technology Translation
11:00am - 11:40am
Global BioPharma Partnerships: Navigating Cross-Border Collaboration and out Licensing
- Strategies for fostering successful cross-border collaborations in the biopharma industry - Key considerations and challenges in out-licensing agreements across global markets - …
Pharma Partnering & Deal Making
11:00am - 11:40am
Venture Capital Trends in Biopharma: Insights into Investor Priorities
- What’s had investors talking in 2026? - How are we thinking about innovation in the current climate - Every investor’s number one priority (or should be)
Capital Markets & Investment Strategies
11:45am - 12:25pm
Beyond the Exit: Should Product Launch Be Your Ultimate Goal?
- How prioritizing IPOs, M&A, or revenue, changes governance, hiring, and program selection compared with goals like platform enablement, open science, or measurable patient outcom…
Market Opportunities & Commercialisation
11:45am - 12:25pm
Big Pharma’s Perspective: What Are They Looking for in Biotech Partners?
- Key attributes and innovations big pharma seeks in biotech partners - How biotech companies can align with big pharma’s strategic goals - Trends in collaboration models and partn…
Pharma Partnering & Deal Making
11:45am - 12:25pm
Building Investor Confidence: Communicating Your Value Proposition
- Highlighting unmet medical needs and market potential - Demonstrating scientific rigor and robust preclinical data - Showcasing a clear roadmap for regulatory and commercial succ…
Capital Markets & Investment Strategies
11:45am - 12:25pm
Overcoming the Valley of Death: Strategies for Advancing Early-Stage Biopharma Startups
- Securing funding and strategic partnerships to bridge critical gaps - Building robust preclinical data to attract investors and collaborators - Navigating regulatory pathways to …
Early Innovation & Technology Translation
1:30pm - 2:10pm
Biotech IPOs 2026: A Candid Reality Check
- Is investor appetite real or limited to highly de‑risked, late‑stage stories - who can actually access public capital now? - Which tangible signals (clinical readouts, cash runwa…
Capital Markets & Investment Strategies

Quick answers

When is LSX Congress USA 2026?: LSX Congress USA 2026 ran Sep 23–24, 2026 at Hynes Convention Center in Boston, United States. The next edition, LSX USA Congress 2027, is Sep 21–23, 2027.
Where is LSX Congress USA 2026 held?: LSX Congress USA 2026 was held at Hynes Convention Center in Boston, United States.
Who is speaking at LSX Congress USA 2026?: ConferenceGrid lists 174 speakers, including Aaron Schuchart (President and CEO, aether THERAPEUTICS), Adam Griffiths (Portfolio Manager, Partnering & Investment, Informa Connect) and Aryeh Ganz (Managing Partner, Cornucopian Capital).
Who sponsors LSX Congress USA 2026?: ConferenceGrid lists 16 sponsors, including Latham & Watkins, Axcelead Drug Discovery Partners,Inc., Brown Rudnick, Ernst & Young and Servier Monde.

Company intelligence

What does it mean when 179 companies show up, and 3 bet on three roles at once?

179 companies. three are betting more than once.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

Who's in the room

3All threespeak · spons · exh

13Sponsoringsponsor only

163Speakingspeaker only

In all three roles

Brown Rudnick·Finnegan·A&O Shearman

Speakers by seniority

86% of the speakers carry senior titles: C-suite, Founder, VP, or Director-level.

C-suite6839%
Founder / Owner3721%
VP-level95%
Director / Head of3621%
Manager / Lead32%
Research / Science11%
Marketing / Brand11%
Advisor / Investor42%
Other roles159%

Of 174 speakers · classified by free-text title

Most-represented companies

#	Company	Roles	Speakers
1	Brown Rudnick	Sponsor · Gold	2
2	Finnegan	Sponsor	2
3	A&O Shearman	Sponsor · Silver	1
4	Axcelead Drug Discovery Partners	Sponsor · Gold	-
5	CMS	Sponsor · Silver	-
6	Davis Polk & Wardwell	Sponsor · Silver	-
7	Ernst & Young	Sponsor · Gold	-
8	Finnegan Law	Sponsor · Silver	-
9	Fish & Richardson	Sponsor · Silver	-
10	Foley Hoag	Sponsor · Silver	-
11	Insmed	Sponsor	-
12	Latham & Watkins	Sponsor · Platinum	-
13	McDermott Will & Schulte	Sponsor · Silver	-
14	Servier Monde	Sponsor · Gold	-

Sponsors by tier

platinum1

6% of 16

gold5

31% of 16

silver8

50% of 16

unspecified2

13% of 16

Related events · by shared sponsors

Conference	Date	City	Shared sponsors
LSX Investival Showcase USA 2027	March 9, 2027	Miami	2

LSX Congress USA 2026

Breaking into New Markets: Strategies for Global Biopharma Expansion

From Bench to Bedside: Accelerating the Translation of Breakthrough Biopharma Innovations

Global BioPharma Partnerships: Navigating Cross-Border Collaboration and out Licensing

Venture Capital Trends in Biopharma: Insights into Investor Priorities

Beyond the Exit: Should Product Launch Be Your Ultimate Goal?

Big Pharma’s Perspective: What Are They Looking for in Biotech Partners?

Building Investor Confidence: Communicating Your Value Proposition

Overcoming the Valley of Death: Strategies for Advancing Early-Stage Biopharma Startups

Biotech IPOs 2026: A Candid Reality Check

179 companies. three are betting more than once.